NCT05548387

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers

A Randomized, Open Label, Single Dose, 4-period Replicate Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety After Administration of a Fixed-dose Combination Drug of HCP2202 or Co-administration of RLD2202 and RLD2203 in Healthy Volunteers Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 54 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2202 and co-administration of each component in fasting condition in healthy volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HCP2202	Take it once per period.
DRUG	RLD2202	Take it once per period.
DRUG	RLD2203	Take it once per period.

Timeline

• Start date: 2022-09-02
• Primary completion: 2022-11-10
• Completion: 2022-11-10
• First posted: 2022-09-21
• Last updated: 2023-09-22

Locations

1 site across 1 country: South Korea